Prospective iterative trial of proteasome inhibitor-based desensitization

American Journal of Transplantation

Volumn 15, Issue 1, 2015, Pages 101-118

  Woodle, E S ^a   Shields, A R ^a,b   Ejaz, N S ^a   Sadaka, B ^a   Girnita, A ^a   Walsh, R C ^a   Alloway, R R ^a   Brailey, P ^a   Cardi, M A ^b   Abu Jawdeh, B G ^a   Roy Chaudhury, P ^a   Govil, A ^a   Mogilishetty, G ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHRIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR BETA3 ANTIGEN; HLA DR BETA4 ANTIGEN; HLA DR BETA5 ANTIGEN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; HLA ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DESENSITIZATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HLA SYSTEM; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY TRANSPLANTATION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PLASMAPHERESIS; PROSPECTIVE STUDY; SOLID; THROMBOCYTOPENIA; ADOLESCENT; DRUG COMBINATION; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; MIDDLE AGED; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEASOME INHIBITORS; PYRAZINES; RISK FACTORS; YOUNG ADULT;

EID: 84919600937     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13050     Document Type: Article

References (23)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011; Annual Data Report: Kidney. Am J Transplant 2013; 13: 11-46.
2. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
3. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023.
4. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009; 87: 268-273.
5. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165-171.
6. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345-351.
7. Nair V, Sawinski D, Akalin E, et al. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant 2012; 26: E261-E268.
8. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
9. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
10. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP., The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407.
11. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
12. Maseda D, Meister S, Neubert K, Herrmann M, Voll RE., Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008; 15: 600-612.
13. Gomez AM, Vrolix K, Martinez-Martinez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011; 186: 2503-2513.
14. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218-1226.
15. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
16. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
17. Batal I, Zeevi A, Lunz JG, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134: 1534-1540.
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0, NCI, NIH, DHHS. March 31, 2003. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed December 5, 2014.
19. Almadrones JMD, Walczak JR, Florio CM, Tian C., Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study. Oncol Nurs Forum 2004; 31: 615-623.
20. Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040-3049.
21. Zachary AA, Montgomery RA, Leffell MS., Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364-370.
22. Amanna IJ, Carlson NE, Slifka MK., Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
23. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548.